Mutations in MAP3K7 that Alter the Activity of the TAK1 Signaling Complex Cause Frontometaphyseal Dysplasia

Emma M. Wade, Philip B. Daniel, Zandra A. Jenkins, Aideen McInerney-Leo, Paul Leo, Tim Morgan, Marie Claude Addor, Lesley C. Adès, Debora Bertola, Axel Bohring, Erin Carter, Tae Joon Cho, Hans Christoph Duba, Elaine Fletcher, Chong A. Kim, Deborah Krakow, Eva Morava-Kozicz, Teresa Neuhann, Andrea Superti-Furga, Irma Veenstra-KnolDagmar Wieczorek, Louise C. Wilson, Raoul C.M. Hennekam, Andrew J. Sutherland-Smith, Tim M. Strom, Andrew O.M. Wilkie, Matthew A. Brown, Emma L. Duncan, David M. Markie, Stephen P. Robertson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Frontometaphyseal dysplasia (FMD) is a progressive sclerosing skeletal dysplasia affecting the long bones and skull. The cause of FMD in some individuals is gain-of-function mutations in FLNA, although how these mutations result in a hyperostotic phenotype remains unknown. Approximately one half of individuals with FMD have no identified mutation in FLNA and are phenotypically very similar to individuals with FLNA mutations, except for an increased tendency to form keloid scars. Using whole-exome sequencing and targeted Sanger sequencing in 19 FMD-affected individuals with no identifiable FLNA mutation, we identified mutations in two genes—MAP3K7, encoding transforming growth factor β (TGF-β)-activated kinase (TAK1), and TAB2, encoding TAK1-associated binding protein 2 (TAB2). Four mutations were found in MAP3K7, including one highly recurrent (n = 15) de novo mutation (c.1454C>T [ p.Pro485Leu]) proximal to the coiled-coil domain of TAK1 and three missense mutations affecting the kinase domain (c.208G>C [p.Glu70Gln], c.299T>A [p.Val100Glu], and c.502G>C [p.Gly168Arg]). Notably, the subjects with the latter three mutations had a milder FMD phenotype. An additional de novo mutation was found in TAB2 (c.1705G>A, p.Glu569Lys). The recurrent mutation does not destabilize TAK1, or impair its ability to homodimerize or bind TAB2, but it does increase TAK1 autophosphorylation and alter the activity of more than one signaling pathway regulated by the TAK1 kinase complex. These findings show that dysregulation of the TAK1 complex produces a close phenocopy of FMD caused by FLNA mutations. Furthermore, they suggest that the pathogenesis of some of the filaminopathies caused by FLNA mutations might be mediated by misregulation of signaling coordinated through the TAK1 signaling complex.

Original languageEnglish (US)
Pages (from-to)392-406
Number of pages15
JournalAmerican Journal of Human Genetics
Volume99
Issue number2
DOIs
StatePublished - Aug 4 2016
Externally publishedYes

Fingerprint

Mutation
Carrier Proteins
Phosphotransferases
Frontometaphyseal dysplasia
Exome
Phenotype
Keloid
Transforming Growth Factors
Missense Mutation
Skull
Cicatrix
Bone and Bones

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Wade, E. M., Daniel, P. B., Jenkins, Z. A., McInerney-Leo, A., Leo, P., Morgan, T., ... Robertson, S. P. (2016). Mutations in MAP3K7 that Alter the Activity of the TAK1 Signaling Complex Cause Frontometaphyseal Dysplasia. American Journal of Human Genetics, 99(2), 392-406. https://doi.org/10.1016/j.ajhg.2016.05.024

Mutations in MAP3K7 that Alter the Activity of the TAK1 Signaling Complex Cause Frontometaphyseal Dysplasia. / Wade, Emma M.; Daniel, Philip B.; Jenkins, Zandra A.; McInerney-Leo, Aideen; Leo, Paul; Morgan, Tim; Addor, Marie Claude; Adès, Lesley C.; Bertola, Debora; Bohring, Axel; Carter, Erin; Cho, Tae Joon; Duba, Hans Christoph; Fletcher, Elaine; Kim, Chong A.; Krakow, Deborah; Morava-Kozicz, Eva; Neuhann, Teresa; Superti-Furga, Andrea; Veenstra-Knol, Irma; Wieczorek, Dagmar; Wilson, Louise C.; Hennekam, Raoul C.M.; Sutherland-Smith, Andrew J.; Strom, Tim M.; Wilkie, Andrew O.M.; Brown, Matthew A.; Duncan, Emma L.; Markie, David M.; Robertson, Stephen P.

In: American Journal of Human Genetics, Vol. 99, No. 2, 04.08.2016, p. 392-406.

Research output: Contribution to journalArticle

Wade, EM, Daniel, PB, Jenkins, ZA, McInerney-Leo, A, Leo, P, Morgan, T, Addor, MC, Adès, LC, Bertola, D, Bohring, A, Carter, E, Cho, TJ, Duba, HC, Fletcher, E, Kim, CA, Krakow, D, Morava-Kozicz, E, Neuhann, T, Superti-Furga, A, Veenstra-Knol, I, Wieczorek, D, Wilson, LC, Hennekam, RCM, Sutherland-Smith, AJ, Strom, TM, Wilkie, AOM, Brown, MA, Duncan, EL, Markie, DM & Robertson, SP 2016, 'Mutations in MAP3K7 that Alter the Activity of the TAK1 Signaling Complex Cause Frontometaphyseal Dysplasia', American Journal of Human Genetics, vol. 99, no. 2, pp. 392-406. https://doi.org/10.1016/j.ajhg.2016.05.024
Wade, Emma M. ; Daniel, Philip B. ; Jenkins, Zandra A. ; McInerney-Leo, Aideen ; Leo, Paul ; Morgan, Tim ; Addor, Marie Claude ; Adès, Lesley C. ; Bertola, Debora ; Bohring, Axel ; Carter, Erin ; Cho, Tae Joon ; Duba, Hans Christoph ; Fletcher, Elaine ; Kim, Chong A. ; Krakow, Deborah ; Morava-Kozicz, Eva ; Neuhann, Teresa ; Superti-Furga, Andrea ; Veenstra-Knol, Irma ; Wieczorek, Dagmar ; Wilson, Louise C. ; Hennekam, Raoul C.M. ; Sutherland-Smith, Andrew J. ; Strom, Tim M. ; Wilkie, Andrew O.M. ; Brown, Matthew A. ; Duncan, Emma L. ; Markie, David M. ; Robertson, Stephen P. / Mutations in MAP3K7 that Alter the Activity of the TAK1 Signaling Complex Cause Frontometaphyseal Dysplasia. In: American Journal of Human Genetics. 2016 ; Vol. 99, No. 2. pp. 392-406.
@article{d071dd62058c4ba28a7ecaa62bb404f6,
title = "Mutations in MAP3K7 that Alter the Activity of the TAK1 Signaling Complex Cause Frontometaphyseal Dysplasia",
abstract = "Frontometaphyseal dysplasia (FMD) is a progressive sclerosing skeletal dysplasia affecting the long bones and skull. The cause of FMD in some individuals is gain-of-function mutations in FLNA, although how these mutations result in a hyperostotic phenotype remains unknown. Approximately one half of individuals with FMD have no identified mutation in FLNA and are phenotypically very similar to individuals with FLNA mutations, except for an increased tendency to form keloid scars. Using whole-exome sequencing and targeted Sanger sequencing in 19 FMD-affected individuals with no identifiable FLNA mutation, we identified mutations in two genes—MAP3K7, encoding transforming growth factor β (TGF-β)-activated kinase (TAK1), and TAB2, encoding TAK1-associated binding protein 2 (TAB2). Four mutations were found in MAP3K7, including one highly recurrent (n = 15) de novo mutation (c.1454C>T [ p.Pro485Leu]) proximal to the coiled-coil domain of TAK1 and three missense mutations affecting the kinase domain (c.208G>C [p.Glu70Gln], c.299T>A [p.Val100Glu], and c.502G>C [p.Gly168Arg]). Notably, the subjects with the latter three mutations had a milder FMD phenotype. An additional de novo mutation was found in TAB2 (c.1705G>A, p.Glu569Lys). The recurrent mutation does not destabilize TAK1, or impair its ability to homodimerize or bind TAB2, but it does increase TAK1 autophosphorylation and alter the activity of more than one signaling pathway regulated by the TAK1 kinase complex. These findings show that dysregulation of the TAK1 complex produces a close phenocopy of FMD caused by FLNA mutations. Furthermore, they suggest that the pathogenesis of some of the filaminopathies caused by FLNA mutations might be mediated by misregulation of signaling coordinated through the TAK1 signaling complex.",
author = "Wade, {Emma M.} and Daniel, {Philip B.} and Jenkins, {Zandra A.} and Aideen McInerney-Leo and Paul Leo and Tim Morgan and Addor, {Marie Claude} and Ad{\`e}s, {Lesley C.} and Debora Bertola and Axel Bohring and Erin Carter and Cho, {Tae Joon} and Duba, {Hans Christoph} and Elaine Fletcher and Kim, {Chong A.} and Deborah Krakow and Eva Morava-Kozicz and Teresa Neuhann and Andrea Superti-Furga and Irma Veenstra-Knol and Dagmar Wieczorek and Wilson, {Louise C.} and Hennekam, {Raoul C.M.} and Sutherland-Smith, {Andrew J.} and Strom, {Tim M.} and Wilkie, {Andrew O.M.} and Brown, {Matthew A.} and Duncan, {Emma L.} and Markie, {David M.} and Robertson, {Stephen P.}",
year = "2016",
month = "8",
day = "4",
doi = "10.1016/j.ajhg.2016.05.024",
language = "English (US)",
volume = "99",
pages = "392--406",
journal = "American Journal of Human Genetics",
issn = "0002-9297",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - Mutations in MAP3K7 that Alter the Activity of the TAK1 Signaling Complex Cause Frontometaphyseal Dysplasia

AU - Wade, Emma M.

AU - Daniel, Philip B.

AU - Jenkins, Zandra A.

AU - McInerney-Leo, Aideen

AU - Leo, Paul

AU - Morgan, Tim

AU - Addor, Marie Claude

AU - Adès, Lesley C.

AU - Bertola, Debora

AU - Bohring, Axel

AU - Carter, Erin

AU - Cho, Tae Joon

AU - Duba, Hans Christoph

AU - Fletcher, Elaine

AU - Kim, Chong A.

AU - Krakow, Deborah

AU - Morava-Kozicz, Eva

AU - Neuhann, Teresa

AU - Superti-Furga, Andrea

AU - Veenstra-Knol, Irma

AU - Wieczorek, Dagmar

AU - Wilson, Louise C.

AU - Hennekam, Raoul C.M.

AU - Sutherland-Smith, Andrew J.

AU - Strom, Tim M.

AU - Wilkie, Andrew O.M.

AU - Brown, Matthew A.

AU - Duncan, Emma L.

AU - Markie, David M.

AU - Robertson, Stephen P.

PY - 2016/8/4

Y1 - 2016/8/4

N2 - Frontometaphyseal dysplasia (FMD) is a progressive sclerosing skeletal dysplasia affecting the long bones and skull. The cause of FMD in some individuals is gain-of-function mutations in FLNA, although how these mutations result in a hyperostotic phenotype remains unknown. Approximately one half of individuals with FMD have no identified mutation in FLNA and are phenotypically very similar to individuals with FLNA mutations, except for an increased tendency to form keloid scars. Using whole-exome sequencing and targeted Sanger sequencing in 19 FMD-affected individuals with no identifiable FLNA mutation, we identified mutations in two genes—MAP3K7, encoding transforming growth factor β (TGF-β)-activated kinase (TAK1), and TAB2, encoding TAK1-associated binding protein 2 (TAB2). Four mutations were found in MAP3K7, including one highly recurrent (n = 15) de novo mutation (c.1454C>T [ p.Pro485Leu]) proximal to the coiled-coil domain of TAK1 and three missense mutations affecting the kinase domain (c.208G>C [p.Glu70Gln], c.299T>A [p.Val100Glu], and c.502G>C [p.Gly168Arg]). Notably, the subjects with the latter three mutations had a milder FMD phenotype. An additional de novo mutation was found in TAB2 (c.1705G>A, p.Glu569Lys). The recurrent mutation does not destabilize TAK1, or impair its ability to homodimerize or bind TAB2, but it does increase TAK1 autophosphorylation and alter the activity of more than one signaling pathway regulated by the TAK1 kinase complex. These findings show that dysregulation of the TAK1 complex produces a close phenocopy of FMD caused by FLNA mutations. Furthermore, they suggest that the pathogenesis of some of the filaminopathies caused by FLNA mutations might be mediated by misregulation of signaling coordinated through the TAK1 signaling complex.

AB - Frontometaphyseal dysplasia (FMD) is a progressive sclerosing skeletal dysplasia affecting the long bones and skull. The cause of FMD in some individuals is gain-of-function mutations in FLNA, although how these mutations result in a hyperostotic phenotype remains unknown. Approximately one half of individuals with FMD have no identified mutation in FLNA and are phenotypically very similar to individuals with FLNA mutations, except for an increased tendency to form keloid scars. Using whole-exome sequencing and targeted Sanger sequencing in 19 FMD-affected individuals with no identifiable FLNA mutation, we identified mutations in two genes—MAP3K7, encoding transforming growth factor β (TGF-β)-activated kinase (TAK1), and TAB2, encoding TAK1-associated binding protein 2 (TAB2). Four mutations were found in MAP3K7, including one highly recurrent (n = 15) de novo mutation (c.1454C>T [ p.Pro485Leu]) proximal to the coiled-coil domain of TAK1 and three missense mutations affecting the kinase domain (c.208G>C [p.Glu70Gln], c.299T>A [p.Val100Glu], and c.502G>C [p.Gly168Arg]). Notably, the subjects with the latter three mutations had a milder FMD phenotype. An additional de novo mutation was found in TAB2 (c.1705G>A, p.Glu569Lys). The recurrent mutation does not destabilize TAK1, or impair its ability to homodimerize or bind TAB2, but it does increase TAK1 autophosphorylation and alter the activity of more than one signaling pathway regulated by the TAK1 kinase complex. These findings show that dysregulation of the TAK1 complex produces a close phenocopy of FMD caused by FLNA mutations. Furthermore, they suggest that the pathogenesis of some of the filaminopathies caused by FLNA mutations might be mediated by misregulation of signaling coordinated through the TAK1 signaling complex.

UR - http://www.scopus.com/inward/record.url?scp=84978880739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978880739&partnerID=8YFLogxK

U2 - 10.1016/j.ajhg.2016.05.024

DO - 10.1016/j.ajhg.2016.05.024

M3 - Article

C2 - 27426733

AN - SCOPUS:84978880739

VL - 99

SP - 392

EP - 406

JO - American Journal of Human Genetics

JF - American Journal of Human Genetics

SN - 0002-9297

IS - 2

ER -